CN109863175A - 用抗-kir3dl2药剂进行的治疗 - Google Patents

用抗-kir3dl2药剂进行的治疗 Download PDF

Info

Publication number
CN109863175A
CN109863175A CN201780064844.4A CN201780064844A CN109863175A CN 109863175 A CN109863175 A CN 109863175A CN 201780064844 A CN201780064844 A CN 201780064844A CN 109863175 A CN109863175 A CN 109863175A
Authority
CN
China
Prior art keywords
kir3dl2
antibody
cell
medicament
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780064844.4A
Other languages
English (en)
Chinese (zh)
Inventor
卡里纳·帕蒂雷尔
埃莱娜·西卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of CN109863175A publication Critical patent/CN109863175A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780064844.4A 2016-10-21 2017-10-19 用抗-kir3dl2药剂进行的治疗 Pending CN109863175A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410880P 2016-10-21 2016-10-21
US62/410,880 2016-10-21
PCT/EP2017/076751 WO2018073363A1 (en) 2016-10-21 2017-10-19 Treatment with anti-kir3dl2 agents

Publications (1)

Publication Number Publication Date
CN109863175A true CN109863175A (zh) 2019-06-07

Family

ID=60268349

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780064844.4A Pending CN109863175A (zh) 2016-10-21 2017-10-19 用抗-kir3dl2药剂进行的治疗

Country Status (8)

Country Link
US (3) US20190248895A1 (enExample)
EP (1) EP3529277A1 (enExample)
JP (1) JP7676109B2 (enExample)
KR (2) KR20190068602A (enExample)
CN (1) CN109863175A (enExample)
AU (1) AU2017345203B2 (enExample)
CA (1) CA3037851A1 (enExample)
WO (1) WO2018073363A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881765C (en) 2012-09-19 2024-02-13 Innate Pharma Kir3dl2 binding agents
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
CN106132989B (zh) 2014-03-14 2020-06-19 先天制药公司 具有增加的稳定性的人源化抗体
BR112021014236A2 (pt) * 2019-01-22 2021-09-28 Innate Pharma Anticorpo, composição farmacêutica, kit e método para predizer ou avaliar a eficácia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640880A (zh) * 2012-09-19 2015-05-20 先天制药公司 Kir3dl2结合剂
WO2015136052A1 (en) * 2014-03-14 2015-09-17 Innate Pharma Humanized antibodies with increased stability
CN105026427A (zh) * 2013-02-20 2015-11-04 依奈特制药公司 特异性结合至kir3dl2的化合物用于治疗外周t细胞淋巴瘤

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
JP2004528824A (ja) 2000-12-18 2004-09-24 アーンスティテュ ナシオナール ド ラ サント エ ド ラ ルシェルシェ メディカル（イー．エンヌ．エス．ウー．エール．エンム．） 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の新規な診断及び治療法
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
US20050260213A1 (en) 2004-04-16 2005-11-24 Scott Koenig Fcgamma-RIIB-specific antibodies and methods of use thereof
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
JP2004126818A (ja) 2002-09-30 2004-04-22 Toshiba Corp 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
KR20060079180A (ko) 2003-07-02 2006-07-05 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
JP2008502322A (ja) 2004-04-30 2008-01-31 イネイト・ファーマ Ｎｋ細胞活性を高めるための組成物および方法
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
DK2287195T3 (da) 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
DK2412728T3 (en) 2004-08-03 2015-04-07 Innate Pharma Therapeutic compositions for cancer, that target 4Ig-B7-H3
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
PL1836225T3 (pl) 2005-01-06 2012-05-31 Novo Nordisk As Czynniki wiążące kir i sposoby ich stosowania
KR20080032065A (ko) 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
FR2894982A1 (fr) 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
WO2007084922A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2379598B1 (en) 2009-01-19 2015-03-11 Innate Pharma Anti-kir3d antibodies
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
WO2012175613A1 (en) 2011-06-21 2012-12-27 Innate Pharma NKp46-MEDIATED NK CELL TUNING
EP2897979B1 (en) 2012-09-19 2019-02-13 Innate Pharma Kir3dl2 binding agents
DK3255062T3 (da) 2013-02-14 2019-10-07 Innate Pharma Anti-nkp46-antistof til diagnosticering af et ikke-kutant perifert t-cellelymfom (ptcl)
WO2016030488A1 (en) * 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
SG11201701387SA (en) 2014-09-16 2017-03-30 Innate Pharma Treatment regimens using anti-nkg2a antibodies
CA2990518A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640880A (zh) * 2012-09-19 2015-05-20 先天制药公司 Kir3dl2结合剂
CN105026427A (zh) * 2013-02-20 2015-11-04 依奈特制药公司 特异性结合至kir3dl2的化合物用于治疗外周t细胞淋巴瘤
WO2015136052A1 (en) * 2014-03-14 2015-09-17 Innate Pharma Humanized antibodies with increased stability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INNATE PHARMA: "Checkpoint antibodies in immuno-oncology", 《HTTP://WWW.INNATE-PHARMA.COM/SITES/DEFAULT/FILES/NY_R_DAY_2016-V4.PDF》 *

Also Published As

Publication number Publication date
US11970535B2 (en) 2024-04-30
KR20230173745A (ko) 2023-12-27
US20240391999A1 (en) 2024-11-28
EP3529277A1 (en) 2019-08-28
US20190248895A1 (en) 2019-08-15
JP7676109B2 (ja) 2025-05-14
AU2017345203A1 (en) 2019-05-02
JP2020500161A (ja) 2020-01-09
AU2017345203B2 (en) 2024-08-01
CA3037851A1 (en) 2018-04-26
KR20190068602A (ko) 2019-06-18
US20210087270A1 (en) 2021-03-25
WO2018073363A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
US12084498B2 (en) Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
AU2015314316B2 (en) Cross reactive Siglec antibodies
US20170233479A1 (en) Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3722314A1 (en) Anti-vista antibodies and fragments
EP3255062B1 (en) Anti-nkp46 antibody for diganosis of a non-cutaneous peripheral t-cell lymphoma (ptcl)
KR20200026254A (ko) 암을 치료하기 위해 인간 siglec-9 에 대한 항체 및 인간 nkg2a 에 대한 항체를 사용하는 조합 치료요법
NO342318B1 (no) Anti-KIR2DL antistoffer og sammensetninger derav.
BR112015006060B1 (pt) Anticorpo monoclonal, composição farmacêutica e uso do anticorpo monoclonal
WO2008087219A1 (en) Compositions and methods for regulating t cell activity
US20240391999A1 (en) Treatment with anti-kir3dl2 agents
US12448442B2 (en) Treatment of T cell lymphoma
RU2835929C2 (ru) Лечение т-клеточной лимфомы
HK40037923A (en) Anti-vista antibodies and fragments
HK1195080A (zh) 调节nk细胞活性的组合物和方法
HK1254953B (en) Anti-vista antibodies and fragments

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190607

RJ01 Rejection of invention patent application after publication